Our top pick for
DexCom Inc is a diagnostics & research business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. DexCom employs 5,500 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$556.54|
|52-week range||$305.63 - $579.00|
|50-day moving average||$545.73|
|200-day moving average||$450.94|
|Wall St. target price||$544.10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.34|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.37%|
|1 month (2021-09-21)||0.50%|
|3 months (2021-07-21)||24.51%|
|6 months (2021-04-21)||38.57%|
|1 year (2020-10-21)||43.50%|
|2 years (2019-10-21)||255.34%|
|3 years (2018-10-19)||331.43%|
|5 years (2016-10-21)||589.81%|
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 102x. In other words, DexCom shares trade at around 102x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 15.186. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $415.8 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.2 billion|
|Operating margin TTM||15.9%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||5.37%|
|Return on equity TTM||31.66%|
|Market capitalisation||$52.7 billion|
TTM: trailing 12 months
There are currently 3.4 million DexCom shares held short by investors – that's known as DexCom's "short interest". This figure is 5.3% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting DexCom shares can be evaluated.
DexCom's "short interest ratio" (SIR) is the quantity of DexCom shares currently shorted divided by the average quantity of DexCom shares traded daily (recently around 545776.11464968). DexCom's SIR currently stands at 6.28. In other words for every 100,000 DexCom shares traded daily on the market, roughly 6280 shares are currently held short.
However DexCom's short interest can also be evaluated against the total number of DexCom shares, or, against the total number of tradable DexCom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DexCom's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DexCom shares in existence, roughly 40 shares are currently held short) or 0.0356% of the tradable shares (for every 100,000 tradable DexCom shares, roughly 36 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DexCom.
Find out more about how you can short DexCom stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
|Total ESG score||29.18|
|Total ESG percentile||50.12|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
We're not expecting DexCom to pay a dividend over the next 12 months.
Over the last 12 months, DexCom's shares have ranged in value from as little as $305.63 up to $579. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.737. This would suggest that DexCom's shares are less volatile than average (for this exchange).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.